Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

892 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antiangiogenic agents.
Stani SC, Capaccetti B, Bonginelli P, Sarmiento R, De Sio L, Fanelli M, Gasparini G. Stani SC, et al. Among authors: gasparini g. Suppl Tumori. 2002 Jul-Aug;1(4):S39-43. Suppl Tumori. 2002. PMID: 12415816 Review. No abstract available.
[Innovative treatment in oncology].
Capaccetti B, Bonginelli P, Sarmiento R, Fanelli M, Longo R, Gattuso D, Gasparini G. Capaccetti B, et al. Among authors: gasparini g. Recenti Prog Med. 2002 Nov;93(11):602-9. Recenti Prog Med. 2002. PMID: 12489478 Review. Italian.
Prognostic and predictive indicators in operable breast cancer.
Morabito A, Magnani E, Gion M, Sarmiento R, Capaccetti B, Longo R, Gattuso D, Gasparini G. Morabito A, et al. Among authors: gasparini g. Clin Breast Cancer. 2003 Feb;3(6):381-90. doi: 10.3816/CBC.2003.n.002. Clin Breast Cancer. 2003. PMID: 12636883 Review.
Thalidomide: a new anticancer drug?
Fanelli M, Sarmiento R, Gattuso D, Carillio G, Capaccetti B, Vacca A, Roccaro AM, Gasparini G. Fanelli M, et al. Among authors: gasparini g. Expert Opin Investig Drugs. 2003 Jul;12(7):1211-25. doi: 10.1517/13543784.12.7.1211. Expert Opin Investig Drugs. 2003. PMID: 12831355 Review.
Safety and activity of the combination of pegylated liposomal doxorubicin and weekly docetaxel in advanced breast cancer.
Morabito A, Gattuso D, Stani SC, Fanelli M, Ferraù F, De Sio L, Castellana MA, Lorusso V, Priolo D, Vitale S, Sarmiento R, Lo Vullo S, Mariani L, Gasparini G. Morabito A, et al. Among authors: gasparini g. Breast Cancer Res Treat. 2004 Aug;86(3):249-57. doi: 10.1023/B:BREA.0000036898.45123.e9. Breast Cancer Res Treat. 2004. PMID: 15567941 Clinical Trial.
The combination of the selective cyclooxygenase-2 inhibitor celecoxib with weekly paclitaxel is a safe and active second-line therapy for non-small cell lung cancer: a phase II study with biological correlates.
Gasparini G, Meo S, Comella G, Stani SC, Mariani L, Gamucci T, Avallone A, Lo Vullo S, Mansueto G, Bonginelli P, Gattuso D, Gion M. Gasparini G, et al. Cancer J. 2005 May-Jun;11(3):209-16. doi: 10.1097/00130404-200505000-00007. Cancer J. 2005. PMID: 16053664 Clinical Trial.
Anti-angiogenic and anti-HER therapy.
Gasparini G, Sarmiento R, Longo R. Gasparini G, et al. Biomed Pharmacother. 2006 Jul;60(6):263-5. doi: 10.1016/j.biopha.2006.06.001. Epub 2006 Jun 23. Biomed Pharmacother. 2006. PMID: 16815667 Review.
892 results